Showing 2441-2450 of 2532 results for "".
- Cynthia Nixon Partners with Galderma and the NRS to Raise Awareness for Rosaceahttps://practicaldermatology.com/news/20130314-cynthia_nixon_partners_with_galderma_and_the_nrs_to_raise_awareness_for_rosacea/2459591/Actress Cynthia Nixon recently joined with dermatologists Rick Fried, MD and Flor Mayoral, MD and a panel of other experts at the "Face to Face with Rosacea: Empowering Professionals and Patients" educational event at the AAD Meeting in Miami. Sponsored by Galderma in conjunction with the National R
- Galderma Launches Online Epiduo Adherence Programhttps://practicaldermatology.com/news/20130312-galderma_launches_online_epiduo_adherence_program/2459593/Galderma announced its new Epiduo TAP (Treatment, Adherence, and Performance) Program, an online and mobile patient platform that educates acne patients ages 13 and older about the proper application of Epiduo (adapalene and benzoyl peroxide 0.1%/2.5%) Gel and encourages acne patients to stay adhere
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or phototherap
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat
- Red Alert: Rosacea Awareness Month Highlights Social Impact and Warning Signs of Rosaceahttps://practicaldermatology.com/news/20130215-red_alert_rosacea_awareness_month_highlights_social_impact_and_warning_signs_of_rosacea/2459615/According to a new patient survey conducted by the NRS, most rosacea patients feel the negative social impact of their condition regardless of which rosacea subtype they may have. While 61 percent of those with only subtype 1 (erythematotelangiectatic) ro
- La Roche-Posay Launches New Pore-Refining Moisturizerhttps://practicaldermatology.com/news/20130201-la_roche-posay_launches_new_pore-refining_moisturizer/2459623/La Roche-Posay's launched the Effaclar MAT Daily Mattifying + Pore-Refining Moisturizer, a formula that contains a unique combination of ingredients that neutralizes shine for lastingly matte, clear, and balanced skin with tightened pores, according to the company. The product is designed for patien
- MedXSafe Phone App Launches for STD Awarenesshttps://practicaldermatology.com/news/20130117-medxsafe_phone_app_launches_for_std_awareness/2459634/Giffen Solutions Inc. released MedXSafe, a new feature to its popular MedXCom Patient platform. Doctors, college health centers, or local health clinics can test for STDs and sign off on MedXSafe that a patient is free of STDs as
- Free Skin Cancer Screenings January 26 in Southeasthttps://practicaldermatology.com/news/20130115-free_skin_cancer_screenings_january_26_in_southeast/2459636/Gulf Coast Dermatology will offer free full-body skin cancer screenings on Saturday, January 26 from 9 a.m. to noon at several of their locations. The screenings are provided by appointment only and are for new patients. Appointments for the
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in